STOCK TITAN

Biodesix (BDSX) Financials

BDSX NASDAQ
Trailing 12 months to September 30, 2026
Revenue $105.2M +31.2% YoY
Net Income -$27.1M n/m YoY
EPS (Diluted) -$2.70 YoY not available
Free Cash Flow -$19.1M n/m YoY
Market Cap $83.8M as of Nov 20, 2026
Price / Sales 0.8x on $105.2M revenue, trailing 12 months to September 30, 2026
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 9.7x on $8.7M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BDSX SEC filings page.

Biodesix, Inc. (BDSX) reported $105.2M in revenue over the twelve months to Sep 30, 2026, up 31.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BDSX FY2025

Revenue growth is narrowing losses, but rising debt and negative equity leave the business financed more by liabilities than assets.

Revenue rose 80.3% from FY2023 to FY2025 while operating margin improved 52.7 percentage points, indicating operating efficiency is improving even though the core business remains loss-making. In FY2025, operating cash flow of -$23.3M nearly matched free cash flow of -$23.5M; the shortfall therefore came mainly from operations, not unusually heavy reinvestment.

Liabilities reached 102.8% of assets in FY2025, leaving negative equity of -$2.5M rather than a conventional equity cushion. Long-term debt rose 24.9% from FY2024 while total assets fell 10.0%, showing that the balance sheet became more debt-dependent even as its asset base contracted.

SG&A was $87.5M against $88.5M of FY2025 revenue, so overhead remained nearly as large as sales despite the revenue expansion. Capital expenditures fell 92.0% from FY2024, yet free cash flow remained negative at -$23.5M; lower reinvestment reduced the cash drain but did not remove the operating deficit.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Cash Runway Dilution R&DIntensity Revenue Progress BurnTrend BalanceSheet 44 / 100
Financial Health Score (5 of 6 dimensions) 44/100
Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed: here 5 of 6, with the others left out rather than counted as zero. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Biodesix, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway
31

Biodesix, Inc. held $19.0M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $23.3M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Biodesix, Inc. scores 31/100 among other emerging companies.

Dilution
n/a

Not available for Biodesix, Inc., so it is left out of the overall score, which averages the 5 of 6 dimensions that can be computed.

R&D Intensity
38

Biodesix, Inc. spent $12.0M on research and development in fiscal year 2025, which was 10.3% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Biodesix, Inc. scores 38/100 among other emerging companies.

Revenue Progress
73

Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. Biodesix, Inc. scores 73/100 on it among other emerging companies.

Burn Trend
48

Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. Biodesix, Inc. scores 48/100 on it among other emerging companies.

Balance Sheet
28

Biodesix, Inc.'s cash, cash equivalents and investments came to $19.0M at the end of fiscal year 2025, against $89.9M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Biodesix, Inc. scores 28/100 among other emerging companies.

Altman Z-Score Distress
-7.24

Biodesix, Inc. scores -7.24, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $497.8M against total assets of $87.5M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
3/8

Biodesix, Inc. passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) passes.

Earnings Quality No Cash Backing
N/A

Biodesix, Inc. reported a net loss of $35.3M while operations used $23.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Biodesix, Inc. reported an operating loss of $27.9M against $7.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$24.0M
YoY+10.4%
QoQ-10.5%
5Y CAGR+29.8%

Biodesix, Inc. generated $24.0M in revenue in Q3 2026. This represents an increase of 10.4% from the same quarter a year earlier. Against the prior quarter it is down 10.5%.

EBITDA
-$4.7M
YoYn/m
QoQn/m
5Y CAGRn/m

Biodesix, Inc.'s EBITDA was -$4.7M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$8.0M
YoYn/m
QoQn/m
5Y CAGRn/m

Biodesix, Inc. reported a net loss of $8.0M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.75
YoYn/m
QoQn/m

Biodesix, Inc. earned -$0.75 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Free Cash Flow
-$7.8M
YoYn/m
QoQn/m
5Y CAGRn/m

Biodesix, Inc. recorded an outflow of $7.8M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$28.4M
YoY+71.1%
QoQ-5.3%
5Y CAGR-9.9%

Biodesix, Inc. held $28.4M in cash against $50.0M in long-term debt as of Q3 2026.

Shares Outstanding
11M
YoY+39.4%
QoQ+5.1%

Biodesix, Inc. had 11M shares outstanding in Q3 2026. This represents an increase of 39.4% from the same quarter a year earlier. Against the prior quarter it is up 5.1%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Operating Margin
-25.4%
YoY+7.0pp
QoQ-5.4pp

Biodesix, Inc.'s operating margin was -25.4% in Q3 2026, reflecting core business profitability. This is up 7.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 5.4 percentage points.

Net Margin
-33.4%
YoY+6.6pp
QoQ-6.3pp

Biodesix, Inc.'s net profit margin was -33.4% in Q3 2026, showing the share of revenue converted to profit. This is up 6.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 6.3 percentage points.

Return on Equity
-92.6%
QoQ-13.0pp

Biodesix, Inc.'s quarterly ROE was -92.6% in Q3 2026: one quarter's net income over shareholder equity, not annualized. Against the prior quarter it is down 13.0 percentage points.

Gross Margin

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$3.0M
YoY+0.1%
QoQ-4.5%
5Y CAGR-1.9%

Biodesix, Inc. invested $3.0M in research and development in Q3 2026. This represents an increase of 0.1% from the same quarter a year earlier. Against the prior quarter it is down 4.5%.

Capital Expenditures
$555K
YoY+1056.3%
QoQ+181.7%
5Y CAGR-10.5%

Biodesix, Inc. invested $555K in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 1056.3% from the same quarter a year earlier. Against the prior quarter it is up 181.7%.

Share Buybacks

Not reported for Q3 2026.

BDSX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BDSX quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$24.0M+10.4%$26.9M+34.2%$25.6M+42.3%$28.8M+40.8%$21.8M+19.9%$20.0M+11.7%$18.0M+21.2%$20.4M+39.3%
R&D Expenses$3.0M+0.1%$3.1M-4.1%$3.3M+14.5%$2.9M+18.9%$3.0M+17.5%$3.3M+27.8%$2.9M+40.7%$2.4M+27.8%
SG&A Expenses$22.5M+3.6%$24.3M+8.3%$24.3M+18.6%$23.0M+13.6%$21.7M+8.5%$22.4M+14.0%$20.4M-0.5%$20.2M+24.4%
Operating Income-$6.1Mn/m-$5.4Mn/m-$6.2Mn/m-$2.0Mn/m-$7.1Mn/m-$9.7Mn/m-$9.1Mn/m-$6.6Mn/m
EBITDA-$4.7Mn/m-$4.0Mn/m-$4.8Mn/m-$580Kn/m-$5.6Mn/m-$8.3Mn/m-$7.7Mn/m-$5.2Mn/m
Interest Expense$2.0M-3.5%$2.0M+4.4%$2.0M+17.3%$2.1M+17.5%$2.1M+1.6%$1.9M-1.9%$1.7M-33.4%$1.8M-24.7%
Income TaxN/AN/A$0n/m$0n/mN/AN/A$0n/m$0n/m
Net Income-$8.0Mn/m-$7.3Mn/m-$7.8Mn/m-$4.0Mn/m-$8.7Mn/m-$11.5Mn/m-$11.1Mn/m-$8.3Mn/m
EPS (Basic)-$0.75n/m-$0.71n/m-$0.81n/m-$0.43n/m-$1.16n/m-$1.56n/m-$1.52-$1.03
EPS (Diluted)-$0.75n/m-$0.71n/m-$0.81n/m-$0.43n/m-$1.16n/m-$1.56n/m-$1.52-$1.03
Diluted Shares (Avg)11M+42.1%10M+40.4%10M+32.3%N/A8M+2.5%7M+15.3%7MN/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.

BDSX Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BDSX quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$93.9M+5.9%$95.3M+8.6%$94.6M+9.7%$87.5M-10.0%$88.7M-13.6%$87.7M-24.3%$86.2M-1.1%$97.2M-1.9%
Current Assets$42.1M+26.1%$43.6M+34.3%$40.9M+38.1%$32.5M-17.6%$33.4M-24.1%$32.4M-43.7%$29.6M+4.0%$39.5M-0.5%
Cash & Equivalents$28.4M+71.1%$30.0M+44.7%$25.6M+45.3%$19.0M-27.7%$16.6M-47.1%$20.7M-50.9%$17.6M+53.2%$26.2M-0.1%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Accounts Receivable$9.1M-28.1%$9.1M+22.3%$9.5M+24.4%$9.0M+5.0%$12.7M+57.7%$7.5M-26.4%$7.6M-22.8%$8.6M+12.0%
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Goodwill$15.0M0.0%$15.0M0.0%$15.0M0.0%$15.0M0.0%$15.0M0.0%$15.0M0.0%$15.0M0.0%$15.0M0.0%
Total Liabilities$85.3M-5.7%$86.2M-0.5%$85.5M+13.7%$89.9M+17.8%$90.4M+20.8%$86.6M+8.8%$75.2M-18.9%$76.4M-19.2%
Current Liabilities$14.2M-21.5%$15.3M+0.9%$14.5M+8.8%$17.4M+21.8%$18.2M+40.0%$15.2M-13.6%$13.3M-57.4%$14.3M-57.2%
Non-Current Liabilities$71.0M-1.8%$70.9M-0.8%$71.0M+14.8%$72.5M+16.8%$72.3M+16.7%$71.4M+15.2%$61.9M+0.6%$62.1M+1.6%
Long-Term Debt$50.0M0.0%$50.0M0.0%$50.0M+24.9%$50.0M+24.9%$50.0M+24.9%$50.0M+24.9%$40.0M-0.1%$40.0M-0.1%
Total Equity$8.7Mn/m$9.1M+703.5%$9.1M-17.4%-$2.5M-111.8%-$1.7M-106.2%$1.1M-96.9%$11.1Mn/m$20.9M+355.8%
Retained Earnings-$520.9Mn/m-$512.8Mn/m-$505.6Mn/m-$497.8Mn/m-$493.8Mn/m-$485.1Mn/m-$473.6Mn/m-$462.5Mn/m

Not reported in any period shown, so not listed: Inventory.

BDSX Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BDSX quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$7.2Mn/m-$1.6Mn/m-$10.2Mn/m$778Kn/m-$8.9Mn/m-$6.6Mn/m-$8.6Mn/m-$4.1Mn/m
Depreciation & Amortization$1.4M-0.5%$1.4M-3.5%$1.4M-3.1%$1.4M-4.3%$1.4M-5.8%$1.4M+1.8%$1.4M+1.4%$1.4M+48.3%
Stock-Based Compensation$852K-19.1%$820K-21.1%$1.1M+14.7%N/A$1.1M-30.5%$1.0M-14.7%$972K-63.2%N/A
Capital Expenditures$555K+1056.3%$197K+286.3%$81K+9.5%$86K-89.7%$48K-79.2%$51K-97.4%$74K-68.4%$839K-71.9%
Free Cash Flow-$7.8Mn/m-$1.8Mn/m-$10.2Mn/m$692Kn/m-$8.9Mn/m-$6.6Mn/m-$8.7Mn/m-$4.9Mn/m
Investing Cash Flow-$600Kn/m-$254Kn/m-$144Kn/m-$104Kn/m-$67Kn/m-$95Kn/m-$137Kn/m-$884Kn/m
Financing Cash Flow$6.2M+28.9%$6.2M-36.3%$16.9M+17319.6%$1.7Mn/m$4.8M+3248.6%$9.8M-80.9%$97K-87.7%-$181K-100.8%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

BDSX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BDSX quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Margin-25.4%+7.0pp-20.1%+28.5pp-24.3%+26.6pp-6.8%+25.7pp-32.4%+14.9pp-48.5%-2.6pp-50.9%+23.5pp-32.6%+14.3pp
Net Margin-33.4%+6.6pp-27.1%+30.2pp-30.5%+31.3pp-13.8%+26.5pp-40.0%+16.5pp-57.3%+3.0pp-61.8%+30.0pp-40.4%+21.9pp
Return on Equity-92.6%-79.5%+928.2pp-85.3%+15.0ppN/AN/A-1007.7%-977.9pp-100.4%-39.5%+160.0pp
Return on Assets-8.6%+1.3pp-7.6%+5.4pp-8.2%+4.6pp-4.5%+3.9pp-9.8%+0.2pp-13.1%-3.7pp-12.9%+2.7pp-8.5%+0.7pp
Current Ratio2.96+1.1x2.85+0.7x2.82+0.6x1.87-0.9x1.84-1.6x2.14-1.1x2.22+1.3x2.76+1.6x
Debt-to-Equity5.765.47-38.5x5.48+1.9xN/AN/A43.95+42.8x3.621.92-6.8x
Liabilities-to-Equity9.839.43-66.7x9.36+2.6xN/AN/A76.10+73.9x6.803.66-17.0x
Asset Turnover0.260.0x0.28+0.1x0.27+0.1x0.33+0.1x0.25+0.1x0.23+0.1x0.210.0x0.21+0.1x
FCF Margin-32.3%+8.7pp-6.6%+26.5pp-40.1%+8.2pp2.4%+26.6pp-41.0%+19.1pp-33.1%-48.3%-24.2%

Not reported in any period shown, so not listed: Gross Margin.

Note: Shareholder equity is negative (-$2.5M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Biodesix, Inc. BDSX FY2025 $88.5M -$35.3M -39.9% $83.8M 44/100
Exagen Inc. XGN FY2025 $66.6M -$20.0M -30.0% $92.1M 49/100
Insight Molecular Diagnostics Inc. IMDX FY2025 $4.1M -$50.2M N/A $64.5M 43/100
Burning Rock Biotech Limited BNR FY2025 $77.2M -$7.9M -10.3% $139.6M 72/100
Precipio, Inc. PRPO FY2025 $24.0M -$363K -1.5% $31.1M 62/100
Quantum Cyber N.V. QUCY FY2025 $537K -$16.2M N/A $44.7M —

Frequently Asked Questions

Biodesix, Inc. (BDSX) reported $88.5M in total revenue for fiscal year 2025. This represents a 24.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Biodesix, Inc. (BDSX) revenue grew by 24.1% year-over-year, from $71.3M to $88.5M in fiscal year 2025.

No, Biodesix, Inc. (BDSX) reported a net loss of $27.1M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $35.3M, with a net profit margin of -39.9%.

Biodesix, Inc. (BDSX) reported diluted earnings per share of -$4.67 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Biodesix, Inc. (BDSX) had EBITDA of -$22.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Biodesix, Inc. (BDSX) had $19.0M in cash and equivalents against $50.0M in long-term debt.

Biodesix, Inc. (BDSX) had an operating margin of -31.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Biodesix, Inc. (BDSX) had a net profit margin of -39.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Biodesix, Inc. (BDSX) recorded an outflow of $23.5M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Biodesix, Inc. (BDSX) recorded an outflow of $23.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Biodesix, Inc. (BDSX) had $87.5M in total assets as of fiscal year 2025, including both current and long-term assets.

Biodesix, Inc. (BDSX) invested $259K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Biodesix, Inc. (BDSX) invested $12.0M in research and development during fiscal year 2025.

Biodesix, Inc. (BDSX) had 10M shares outstanding as of fiscal year 2025.

Biodesix, Inc. (BDSX) had a current ratio of 1.87 as of fiscal year 2025, which is generally considered healthy.

Biodesix, Inc. (BDSX) had a return on assets of -40.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Biodesix, Inc. (BDSX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $83.8M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Biodesix, Inc. (BDSX) trades at 0.8x sales, its market capitalization divided by $105.2M revenue, trailing 12 months to September 30, 2026. The market capitalization is $83.8M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Biodesix, Inc. (BDSX) held $19.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $23.3M over that year. Dividing the one by the other, the reported balance equals about 10 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Biodesix, Inc. (BDSX) has negative shareholder equity of -$2.5M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Biodesix, Inc. (BDSX) has an Altman Z-Score of -7.24, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Biodesix, Inc. (BDSX) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Biodesix, Inc. (BDSX) reported a net loss of $35.3M while operations used $23.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Biodesix, Inc. (BDSX) reported an operating loss of $27.9M against $7.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Biodesix, Inc. (BDSX) scores 44 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. For Biodesix, Inc. it averages the 5 of 6 dimensions that can be computed; the others are left out rather than counted as zero. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top